Astena Holdings Co., Ltd.

TSE:8095 Rapport sur les actions

Capitalisation boursière : JP¥19.8b

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Astena Holdings Résultats passés

Passé contrôle des critères 2/6

Astena Holdings's earnings have been declining at an average annual rate of -13.5%, while the Pharmaceuticals industry saw earnings growing at 5.4% annually. Revenues have been declining at an average rate of 4.8% per year. Astena Holdings's return on equity is 7.2%, and it has net margins of 3.9%.

Informations clés

-13.5%

Taux de croissance des bénéfices

-18.1%

Taux de croissance du BPA

Pharmaceuticals Croissance de l'industrie3.4%
Taux de croissance des recettes-4.8%
Rendement des fonds propres7.2%
Marge nette3.9%
Prochaine mise à jour des résultats11 Oct 2024

Mises à jour récentes des performances passées

Recent updates

Astena Holdings Co., Ltd.'s (TSE:8095) Revenues Are Not Doing Enough For Some Investors

Aug 07
Astena Holdings Co., Ltd.'s (TSE:8095) Revenues Are Not Doing Enough For Some Investors

Astena Holdings (TSE:8095) Has Affirmed Its Dividend Of ¥9.00

Mar 04
Astena Holdings (TSE:8095) Has Affirmed Its Dividend Of ¥9.00

Ventilation des recettes et des dépenses

Comment Astena Holdings gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.


Historique des gains et des recettes

TSE:8095 Recettes, dépenses et bénéfices (JPY Millions )
DateRecettesLes revenusDépenses G+ADépenses de R&D
31 May 2453,2182,09314,2480
29 Feb 2452,6251,61714,1630
30 Nov 2351,9841,16214,0440
31 Aug 2353,38218213,6530
31 May 2351,559-58013,7500
28 Feb 2350,136-7613,6080
30 Nov 2249,63657913,5410
31 Aug 2255,5231,21213,9750
31 May 2261,0071,69313,8480
28 Feb 2267,6321,78713,7510
30 Nov 2172,3221,73613,4940
31 Aug 2171,5041,54313,4160
31 May 2170,7582,36612,9400
28 Feb 2167,7452,18512,2990
30 Nov 2065,3411,98311,8130
31 Aug 2062,8151,95711,9400
31 May 2061,4251,23411,5370
29 Feb 2061,4631,38011,2810
30 Nov 1961,6471,53311,0560
31 Aug 1962,3271,53710,9100
31 May 1962,1131,68810,7900
28 Feb 1961,2851,71810,6740
30 Nov 1860,0831,41410,5940
31 Aug 1859,3211,41810,4170
31 May 1858,36899110,3520
28 Feb 1857,84974510,2820
30 Nov 1757,3871,24110,1080
31 Aug 1756,6335679,9500
31 May 1756,3207809,8700
28 Feb 1755,4595089,8610
30 Nov 1655,12189,8920
31 Aug 1654,6542229,9180
31 May 1654,750-2589,8510
29 Feb 1655,174-1389,7610
30 Nov 1555,422-1439,9230
31 Aug 1555,6931489,9230
31 May 1554,92539210,2020
28 Feb 1554,60247510,1710
30 Nov 1454,1454969,9660
31 Aug 1453,6484629,8200
31 May 1453,5287219,4890
28 Feb 1453,0917839,3800
30 Nov 1352,4657449,4880
31 Aug 1352,2928319,4880

Des revenus de qualité: 8095 has high quality earnings.

Augmentation de la marge bénéficiaire: 8095 became profitable in the past.


Analyse des flux de trésorerie disponibles par rapport aux bénéfices


Analyse de la croissance passée des bénéfices

Tendance des revenus: 8095's earnings have declined by 13.5% per year over the past 5 years.

Accélération de la croissance: 8095 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Bénéfices par rapport au secteur d'activité: 8095 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (8.6%).


Rendement des fonds propres

ROE élevé: 8095's Return on Equity (7.2%) is considered low.


Rendement des actifs


Rendement des capitaux employés


Découvrir des entreprises performantes dans le passé